Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Nicotinamide Mononucleotide (NMN) is a precursor to nicotinamide adenine dinucleotide (NAD+), a molecule crucial for cellular metabolism and energy production. Research interest in NMN has grown due to its role in supporting NAD+ levels, which decline with age and in metabolic disorders. Metabolic syndrome, characterized by insulin resistance, obesity, dyslipidemia, and hypertension, is associated with impaired NAD+ metabolism.

Preclinical studies in mice have shown that NMN supplementation can improve insulin sensitivity, enhance lipid metabolism, and reduce inflammation, thereby ameliorating several features of metabolic syndrome. These effects are thought to be mediated by the restoration of NAD+ pools, which activate sirtuin enzymes involved in metabolic regulation.

Human evidence is still limited. A few small clinical trials have reported that oral NMN supplementation may improve insulin sensitivity and some markers of metabolic health in overweight or prediabetic adults. However, these studies are preliminary, often short-term, and involve small sample sizes. No large-scale, long-term randomized controlled trials have definitively established NMN’s efficacy for treating or preventing metabolic syndrome in humans.

In summary, while there is promising preclinical and early clinical evidence that NMN may benefit metabolic syndrome, the overall strength of the evidence is modest at present, warranting a rating of 2 out of 5. Further robust human studies are needed before NMN can be recommended with confidence for this condition.

More about Nicotinamide Mononucleotide
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Nicotinamide Mononucleotide

Products containing Nicotinamide Mononucleotide